|
|
 |
|
Viewing report
|
|
|
|
It's All About the Biomarkers: How 2008's Biomarker-Based Partnering Is Driving Personalized Medicine
Decision Resources, Inc., Dec 2008, Pages: 35
Introduction
Biomarkers—physical characteristics that are objectively evaluated as indicators of normal biological
processes, pathogenic processes, or pharmacological responses to therapeutic intervention—are high-value-added commodities in drug and diagnostics discovery and development, and biomarker-based strategies are the key to success in personalized medicine. In 2008, these strategies were manifest in a variety of biomarker centered partnerships that involved pharmaceutical and biotech companies, academic institutions, and government agencies and in several significant M&As that we examine in this report.
Get the Answers You Need to Shape Your Strategy
- The push for personalized - medicine is gathering momentum. What are the driving forces? What are the advantages and challenges of the personalized medicine paradigm shift for pharma companies? For diagnostics companies? For healthcare in general?
- Biomarker proponents often point to the success of Genentech/Roche/Chugai’s Herceptin to illustrate the value of biomarker-based drug/diagnostic development. What makes Herceptin a prime example? What other success stories in biomarker-related research, development, partnering, and regulatory approval can companies use as models?
- Researchers at your company have discovered a target that is amenable to biomarker development, drug development, or both. What are your options? When should you pursue an alliance? What are the benefits of partnering, or not partnering, to realize the full potential of the discovery? What are other companies doing?
- Despite the promise of personalized medicine, investment of resources in biomarkers presents challenges. What are the pros and cons of investing in biomarkers? What can companies do to secure their buy-in?
Scope
- Key trends in biomarker partnering, November 2 - 007 to November 2008: biopharmaceutical
and diagnostics company alliances, diagnostics company partnerships, industry and academia collaborations, and government-sponsored, biomarker-based product development.
- Five biomarker deal models: whole company acquisitions, asset purchases, collaborations, licensing deals, and government-funded deals.
- Biomarker deal drivers: demand for more-precise diagnostics and safer, more-effective drugs; Lower-cost, lower-risk drug development; growth potential of the diagnostics market.
- Expert Commentary: Spectrum Senior Program Manager Lulu Pickering, Ph.D., offers “Ten Insights on Integrating Personalized Medicine into Pharma Business Strategies.”
Customers who bought this item also bought
Companion Biomarkers in Drug Development
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
Biomarkers: The Future of Next-Generation Drug R&D
Companion Diagnostics in Personalized Medicine and Cancer Therapy
How Overcoming the Challenge of Biomarker Validation Can Pay Off for Drug and Diagnostic Developers
Biomarkers 2008
Enabling Oncology Diagnostics: Predictive Biomarkers Based on Genes, Proteins, and Pathways
Blood Biomarkers and Beyond: Biomarker and Diagnostic Opportunities in Cardiovascular Disease
Biomarkers - Technologies, Markets and Companies
Molecular Biomarkers for Clinical Diagnostics and Drug Discovery and Development
Advances in Biomarkers
What Is the Future Role of Predictive Safety Biomarkers in Drug Development?
|
|
|
|
